Oct 31st Day 3

Veterinary
09:00

Chair’s opening remarks

Vaccine Safety
09:00

Chair’s opening remarks

Immuno-oncology
09:00

Chair’s opening remarks

Bioprocess & Manufacture
09:00

Chair’s opening remarks

Partnerships
09:00

Chair’s opening remarks

09:09

International Partnerships & DCVMs

09:09

Manufacturing Platforms

09:09

Oncolytic Viruses

09:09

Prevention & Response: Infectious Diseases

09:09

Vaccine Safety & Decision Making

Bioprocess & Manufacture
09:10

Novel Technologies for Intensified Vaccine Processing

Vaccine Safety
09:10

Panel: Building vaccine confidence and resilient immunization systems – The role of communications

The role of communications in vaccine hesitancy andconfidence?-How can stakeholdersfrom patient advocates, journalists, healthcare providers, policymakers to industry – apply behavioral science insights to shape more effective communications around vaccination and improve vaccination acceptance?-What are the attributes of a resilient immunization system, and how can we collaborate to manage threats to vaccine confidence and better anticipate and mitigate issues in the future?
Bioprocess & Manufacture
09:40

New game changing technologies for vaccine production

Veterinary
09:40

Optimizing models for tracking disease emergence globally

Bioprocess & Manufacture
10:10

Continuous production & downstream processing for purification of virus particles/viral antigens

Partnerships
10:10

International funding

Immuno-oncology
10:10

LOAd703- Immunostimulatory oncolytic virus as a monotherapy and in combination

10:40

Morning Networking Break

Vaccine Safety
11:20

Adult Vaccines – What’s needed for a rapidly changing demographic?

Same data, different results: an archetype analysis of adult vaccine decision making and uptake in 34 countriesAdult Immunization Evidence & Policy: Issues for the next decadeIssues for implementation of adult immunization programsIntroducing the International Council on Adult ImmunizationPanel with all speakers: Accelerating progress – what do we do differently?
Immuno-oncology
11:20

Overcoming antibody drug development challenges

-Translating antibody therapies to the clinic – The devil is in the detail
11:29

Antibody Therapy

Immuno-oncology
11:50

Clinical Developments: BiTE® antibody construct targeting CD33 in AML

Bioprocess & Manufacture
11:50

Panel: From development to commercialization of vaccines

  • Lessons learned from various vaccine – hurdles to avoid in order to reach large scale manufacture
  • Are we incorporating computational modelling and AI for smarter manufacturing?
Partnerships
12:20

The role of industry in Public-Private-Partnerships

12:50

Afternoon Networking Lunch

13:49

AFTERNOON PLENARY TALKS

13:50

Chair Opening Remarks

Mariagrazia Pizza
14:00

What’s next? Working towards Immunology 2.0 and beyond

  • How has genomics, virology and epidemiology helped revolutionise the way we develop vaccines?
  • New scientific approaches to more targeted bacterial vaccines using computational modelling and mAb mapping
  • What progress has been made with all this new information to hand – is it translational?
  • What policy considerations and challenges should we anticipate with these technologies? Governmental challenges
Panel discussion
15:00

Eliminating (or Eradicating) Global Infectious Diseases

  • Key targets- Polio, Measles
  • What’s the vaccinations strategy once a disease is eradicated?
  • Plans in place for developing countries?
16:00

Chair’s closing remarks and close of congress

last published: 18/Jul/19 08:45 GMT

Sign Up for Event Updates